Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02727803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02727803 · ClinicalTrials.gov record · last posted 2026-07-30

Personalized NK Cell Therapy in CBT

StatusRecruiting
PhasePhase 2
Started2016-05-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.

Amendment record 36 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 36 times since 2016-03-30; most recent amendment 2026-05-20. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2017-07-11
Status change Active, Not Recruiting→Recruitingv9
2017-07-07
Status change Recruiting→Active, Not Recruitingv8
2016-05-19
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT02727803
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia +18 more
Enrollment 100 participants
Start Date 2016-05-19
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30